Science 9 January 1987: Vol. 235. no. 4785, pp. 177 - 182 DOI: 10.1126/science.3798106

Prev | Table of Contents | Next

Articles

Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients.

M. Lae, J. Couturier, S. Oudard, F. Radvanyi, P. Beuzeboc, and A. Vieillefond (2009)
Ann. Onc.
 |  Abstract »  |  Full Text »  |  PDF »

A Perspective on Challenges and Issues in Biomarker Development and Drug and Biomarker Codevelopment.

S. E. Taube, G. M. Clark, J. E. Dancey, L. M. McShane, C. C. Sigman, and S. I. Gutman (2009)
J Natl Cancer Inst 101, 1453-1463
 |  Abstract »  |  Full Text »  |  PDF »

c-Src Associates with ErbB2 through an Interaction between Catalytic Domains and Confers Enhanced Transforming Potential.

R. Marcotte, L. Zhou, H. Kim, C. D. Roskelly, and W. J. Muller (2009)
Mol. Cell. Biol. 29, 5858-5871
 |  Abstract »  |  Full Text »  |  PDF »

Phase I Active Immunotherapy With Combination of Two Chimeric, Human Epidermal Growth Factor Receptor 2, B-Cell Epitopes Fused to a Promiscuous T-Cell Epitope in Patients With Metastatic and/or Recurrent Solid Tumors.

P. T.P. Kaumaya, K. C. Foy, J. Garrett, S. V. Rawale, D. Vicari, J. M. Thurmond, T. Lamb, A. Mani, Y. Kane, C. R. Balint, et al. (2009)
J. Clin. Oncol. 27, 5270-5277
 |  Abstract »  |  Full Text »  |  PDF »

Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Central Nervous System Metastases.

B. Leyland-Jones (2009)
J. Clin. Oncol. 27, 5278-5286
 |  Abstract »  |  Full Text »  |  PDF »

18F-FDG Small-Animal PET/CT Differentiates Trastuzumab-Responsive from Unresponsive Human Breast Cancer Xenografts in Athymic Mice.

K. McLarty, A. Fasih, D. A. Scollard, S. J. Done, D. C. Vines, D. E. Green, D. L. Costantini, and R. M. Reilly (2009)
J. Nucl. Med. 50, 1848-1856
 |  Abstract »  |  Full Text »  |  PDF »

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer.

D. Zhang, T. A. LaFortune, S. Krishnamurthy, F. J. Esteva, M. Cristofanilli, P. Liu, A. Lucci, B. Singh, M.-C. Hung, G. N. Hortobagyi, et al. (2009)
Clin. Cancer Res. 15, 6639-6648
 |  Abstract »  |  Full Text »  |  PDF »

A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies.

H. A. Burris III, C. W. Taylor, S. F. Jones, K. M. Koch, M. J. Versola, N. Arya, R. A. Fleming, D. A. Smith, L. Pandite, N. Spector, et al. (2009)
Clin. Cancer Res. 15, 6702-6708
 |  Abstract »  |  Full Text »  |  PDF »

Immunoselection of Breast and Ovarian Cancer Cells with Trastuzumab and Natural Killer Cells: Selective Escape of CD44high/CD24low/HER2low Breast Cancer Stem Cells.

F. Reim, Y. Dombrowski, C. Ritter, M. Buttmann, S. Hausler, M. Ossadnik, M. Krockenberger, D. Beier, C. P. Beier, J. Dietl, et al. (2009)
Cancer Res. 69, 8058-8066
 |  Abstract »  |  Full Text »  |  PDF »

Trastuzumab: A Picky Partner?.

H. L. McArthur and C. A. Hudis (2009)
Clin. Cancer Res. 15, 6311-6313
 |  Abstract »  |  Full Text »  |  PDF »

Estrogen Receptor-Negative Breast Cancer: New Insights into Subclassification and Targeting.

J. J. Zhao and D. P. Silver (2009)
Clin. Cancer Res. 15, 6309-6310
 |  Abstract »  |  Full Text »  |  PDF »

Emerging Technologies for Assessing HER2 Amplification.

F. Penault-Llorca, M. Bilous, M. Dowsett, W. Hanna, R. Y. Osamura, J. Ruschoff, and M. van de Vijver (2009)
Am J Clin Pathol 132, 539-548
 |  Abstract »  |  Full Text »  |  PDF »

HER2 Status on Persistent Disseminated Tumor Cells after Adjuvant Therapy May Differ from Initial HER2 Status on Primary Tumor.

N. KRAWCZYK, M. BANYS, H. NEUBAUER, E.-F. SOLOMAYER, C. GALL, M. HAHN, S. BECKER, R. BACHMANN, D. WALLWIENER, and T. FEHM (2009)
Anticancer Res 29, 4019-4024
 |  Abstract »  |  Full Text »  |  PDF »

Clear Cell Papulosis: A Connection of Clear Cells to Toker Cells or Paget Disease.

Y. Yu, S. Sukhatme, and D. S. Loo (2009)
Arch Dermatol 145, 1066-1068
 |  Full Text »  |  PDF »

Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents.

G. Riccio, G. Esposito, E. Leoncini, R. Contu, G. Condorelli, M. Chiariello, P. Laccetti, S. Hrelia, G. D'Alessio, and C. De Lorenzo (2009)
FASEB J 23, 3171-3178
 |  Abstract »  |  Full Text »  |  PDF »

Tumor necrosis factor deficiency inhibits mammary tumorigenesis and a tumor necrosis factor neutralizing antibody decreases mammary tumor growth in neu/erbB2 transgenic mice.

M. A. Warren, S. F. Shoemaker, D. J. Shealy, W. Bshar, and M. M. Ip (2009)
Mol. Cancer Ther. 8, 2655-2663
 |  Abstract »  |  Full Text »  |  PDF »

Perspectives and Attitudes on the Use of Adjuvant Chemotherapy and Trastuzumab in Older Adults with HER-2+ Breast Cancer: A Survey of Oncologists.

A. Hurria, F. L. Wong, S. Pal, C. T. Chung, S. Bhatia, J. Mortimer, G. Somlo, S. Hurvitz, D. Villaluna, and A. Naeim (2009)
Oncologist 14, 883-890
 |  Abstract »  |  Full Text »  |  PDF »

Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer.

Y. Nadler, A. M. Gonzalez, R. L. Camp, D. L. Rimm, H. M. Kluger, and Y. Kluger (2009)
Ann. Onc.
 |  Abstract »  |  Full Text »  |  PDF »

Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer.

R. S. Finn, M. F. Press, J. Dering, M. Arbushites, M. Koehler, C. Oliva, L. S. Williams, and A. Di Leo (2009)
J. Clin. Oncol. 27, 3908-3915
 |  Abstract »  |  Full Text »  |  PDF »

Long-term Outcome and Pattern of Relapse after Neoadjuvant Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 2-positive Primary Breast Cancer.

C. Shimizu, N. Masuda, K. Yoshimura, H. Tsuda, M. Mano, M. Ando, K. Tamura, and Y. Fujiwara (2009)
Jpn. J. Clin. Oncol. 39, 484-490
 |  Abstract »  |  Full Text »  |  PDF »

Tissue microarray-based study of patients with lymph node-negative breast cancer shows that HER2/neu overexpression is an important predictive marker of poor prognosis.

Y. H. Choi, J. H. Ahn, S.-B. Kim, K.-H. Jung, G.-Y. Gong, M.-J. Kim, B.-H. Son, S.-H. Ahn, and W. K. Kim (2009)
Ann. Onc. 20, 1337-1343
 |  Abstract »  |  Full Text »  |  PDF »

Loss of Anti-proliferative Effect of All-trans Retinoic Acid in Advanced Stage of Breast Carcinogenesis.

E. H. AHN, C.-C. CHANG, and D. A. TALMAGE (2009)
Anticancer Res 29, 2899-2904
 |  Abstract »  |  Full Text »  |  PDF »

Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib.

C. C. Leow, J. Chesebrough, K. T. Coffman, C. A. Fazenbaker, J. Gooya, D. Weng, S. Coats, D. Jackson, B. Jallal, and Y. Chang (2009)
Mol. Cancer Ther. 8, 2131-2141
 |  Abstract »  |  Full Text »  |  PDF »

An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance.

D. Mitra, M. J. Brumlik, S. U. Okamgba, Y. Zhu, T. T. Duplessis, J. G. Parvani, S. M. Lesko, E. Brogi, and F. E. Jones (2009)
Mol. Cancer Ther. 8, 2152-2162
 |  Abstract »  |  Full Text »  |  PDF »

Adjuvant Trastuzumab Induces Ventricular Remodeling Despite Aerobic Exercise Training.

M. J. Haykowsky, J. R. Mackey, R. B. Thompson, L. W. Jones, and D. I. Paterson (2009)
Clin. Cancer Res. 15, 4963-4967
 |  Abstract »  |  Full Text »  |  PDF »

HER2 Testing and Subsequent Trastuzumab Treatment for Breast Cancer in a Managed Care Environment.

J. J. Barron, M. J. Cziraky, T. Weisman, and D. G. Hicks (2009)
Oncologist 14, 760-768
 |  Abstract »  |  Full Text »  |  PDF »

Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.

Y. Kataoka, T. Mukohara, H. Shimada, N. Saijo, M. Hirai, and H. Minami (2009)
Ann. Onc.
 |  Abstract »  |  Full Text »  |  PDF »

Expression of ER-{alpha}36, a Novel Variant of Estrogen Receptor {alpha}, and Resistance to Tamoxifen Treatment in Breast Cancer.

L. Shi, B. Dong, Z. Li, Y. Lu, T. Ouyang, J. Li, T. Wang, Z. Fan, T. Fan, B. Lin, et al. (2009)
J. Clin. Oncol. 27, 3423-3429
 |  Abstract »  |  Full Text »  |  PDF »

Imaging Biomarkers Predict Response to Anti-HER2 (ErbB2) Therapy in Preclinical Models of Breast Cancer.

C. Shah, T. W. Miller, S. K. Wyatt, E. T. McKinley, M. G. Olivares, V. Sanchez, D. D. Nolting, J. R. Buck, P. Zhao, M. S. Ansari, et al. (2009)
Clin. Cancer Res. 15, 4712-4721
 |  Abstract »  |  Full Text »  |  PDF »

PTEN Deficiency in a Luminal ErbB-2 Mouse Model Results in Dramatic Acceleration of Mammary Tumorigenesis and Metastasis.

B. Schade, T. Rao, N. Dourdin, R. Lesurf, M. Hallett, R. D. Cardiff, and W. J. Muller (2009)
J. Biol. Chem. 284, 19018-19026
 |  Abstract »  |  Full Text »  |  PDF »

Justification of the Change From 10% to 30% for the Immunohistochemical HER2 Scoring Criterion in Breast Cancer.

Y.-H. Liu, F.-P. Xu, J.-Y. Rao, H.-G. Zhuang, X.-L. Luo, L. Li, D.-L. Luo, F. Zhang, and J. Xu (2009)
Am J Clin Pathol 132, 74-79
 |  Abstract »  |  Full Text »  |  PDF »

Automated Cellular Imaging System III for Assessing HER2 Status in Breast Cancer Specimens: Development of a Standardized Scoring Method That Correlates With FISH.

D. M. Minot, B. R. Kipp, R. M. Root, R. G. Meyer, C. A. Reynolds, A. Nassar, M. R. Henry, and A. C. Clayton (2009)
Am J Clin Pathol 132, 133-138
 |  Abstract »  |  Full Text »  |  PDF »

Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC).

M. Arnedos, A. Nerurkar, P. Osin, R. A'Hern, I. E. Smith, and M. Dowsett (2009)
Ann. Onc.
 |  Abstract »  |  Full Text »  |  PDF »

What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer?.

C. H. Barrios, C. Sampaio, J. Vinholes, and R. Caponero (2009)
Ann. Onc. 20, 1157-1162
 |  Abstract »  |  Full Text »  |  PDF »

Aiming for a Direct Hit: Combining Molecular Imaging with Targeted Cancer Therapy.

R. M. Reilly (2009)
J. Nucl. Med. 50, 1017-1019
 |  Full Text »  |  PDF »

Immunoimaging of CXCR4 Expression in Brain Tumor Xenografts Using SPECT/CT.

S. Nimmagadda, M. Pullambhatla, and M. G. Pomper (2009)
J. Nucl. Med. 50, 1124-1130
 |  Abstract »  |  Full Text »  |  PDF »

Cell Lines as Candidate Reference Materials for Quality Control of ERBB2 Amplification and Expression Assays in Breast Cancer.

Y. Xiao, X. Gao, S. Maragh, W. G. Telford, and A. Tona (2009)
Clin. Chem. 55, 1307-1315
 |  Abstract »  |  Full Text »  |  PDF »

AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist.

D. R. Rhodes, B. Ateeq, Q. Cao, S. A. Tomlins, R. Mehra, B. Laxman, S. Kalyana-Sundaram, R. J. Lonigro, B. E. Helgeson, M. S. Bhojani, et al. (2009)
PNAS 106, 10284-10289
 |  Abstract »  |  Full Text »  |  PDF »

Disease-Free Survival According to Degree of HER2 Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial.

M. Dowsett, M. Procter, W. McCaskill-Stevens, E. de Azambuja, U. Dafni, J. Rueschoff, B. Jordan, S. Dolci, M. Abramovitz, O. Stoss, et al. (2009)
J. Clin. Oncol. 27, 2962-2969
 |  Abstract »  |  Full Text »  |  PDF »

HER-2/neu analysis in breast cancer bone metastases.

J Zustin, K Boddin, M C Tsourlakis, E Burandt, M Mirlacher, F Jaenicke, J Izbicki, W Ruether, J M Rueger, C Bokemeyer, et al. (2009)
J. Clin. Pathol. 62, 542-546
 |  Abstract »  |  Full Text »  |  PDF »

Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging.

E. C.F. Dijkers, J. G.W. Kosterink, A. P. Rademaker, L. R. Perk, G. A.M.S. van Dongen, J. Bart, J. R. de Jong, E. G.E. de Vries, and M. N. Lub-de Hooge (2009)
J. Nucl. Med. 50, 974-981
 |  Abstract »  |  Full Text »  |  PDF »

Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.

K. L. Blackwell, M. D. Pegram, E. Tan-Chiu, L. S. Schwartzberg, M. C. Arbushites, J. D. Maltzman, J. K. Forster, S. D. Rubin, S. H. Stein, and H. J. Burstein (2009)
Ann. Onc. 20, 1026-1031
 |  Abstract »  |  Full Text »  |  PDF »

Treatment Options for Breast Cancer Resistant to Anthracycline and Taxane.

A. Moreno-Aspitia and E. A. Perez (2009)
Mayo Clin. Proc. 84, 533-545
 |  Abstract »  |  Full Text »  |  PDF »

The Trifunctional Antibody Ertumaxomab Destroys Tumor Cells That Express Low Levels of Human Epidermal Growth Factor Receptor 2.

M. Jager, A. Schoberth, P. Ruf, J. Hess, and H. Lindhofer (2009)
Cancer Res. 69, 4270-4276
 |  Abstract »  |  Full Text »  |  PDF »

Adiponectin Deficiency Limits Tumor Vascularization in the MMTV-PyV-mT Mouse Model of Mammary Cancer.

M. S. Denzel, L. W. Hebbard, G. Shostak, L. Shapiro, R. D. Cardiff, and B. Ranscht (2009)
Clin. Cancer Res. 15, 3256-3264
 |  Abstract »  |  Full Text »  |  PDF »

Alterations in the TOP2A and HER2 Genes: Association With Adjuvant Anthracycline Sensitivity in Human Breast Cancers.

D. J. Slamon and M. F. Press (2009)
J Natl Cancer Inst 101, 615-618
 |  Full Text »  |  PDF »

Genotypic Intratumoral Heterogeneity in Breast Carcinoma With HER2/neu Amplification: Evaluation According to ASCO/CAP Criteria.

M. Brunelli, E. Manfrin, G. Martignoni, K. Miller, A. Remo, D. Reghellin, S. Bersani, S. Gobbo, A. Eccher, M. Chilosi, et al. (2009)
Am J Clin Pathol 131, 678-682
 |  Abstract »  |  Full Text »  |  PDF »

Finding Biomarkers of Cancer Drug Resistance through RNA Interference-Based Genetic Screens.

R. Bernards (2009)
Am. Assoc. Cancer Res. Educ. Book 2009, 253-257
 |  Full Text »  |  PDF »

The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

L. C. Benavides, J. D. Gates, M. G. Carmichael, R. Patel, J. P. Holmes, M. T. Hueman, E. A. Mittendorf, D. Craig, A. Stojadinovic, S. Ponniah, et al. (2009)
Clin. Cancer Res. 15, 2895-2904
 |  Abstract »  |  Full Text »  |  PDF »

Tumor detection and elimination by a targeted gallium corrole.

H. Agadjanian, J. Ma, A. Rentsendorj, V. Valluripalli, J. Y. Hwang, A. Mahammed, D. L. Farkas, H. B. Gray, Z. Gross, and L. K. Medina-Kauwe (2009)
PNAS 106, 6105-6110
 |  Abstract »  |  Full Text »  |  PDF »

Chromogenic In Situ Hybridization Is a Reliable Method for Detecting HER2 Gene Status in Breast Cancer: A Multicenter Study Using Conventional Scoring Criteria and the New ASCO/CAP Recommendations.

Y. Gong, W. Sweet, Y.-J. Duh, L. Greenfield, Y. Fang, J. Zhao, E. Tarco, W. F. Symmans, J. Isola, and N. Sneige (2009)
Am J Clin Pathol 131, 490-497
 |  Abstract »  |  Full Text »  |  PDF »

Review Article: Targeted Therapy: Comprehensive Review.

R. L. Barros Costa (2009)
American Journal of Hospice and Palliative Medicine 26, 137-146
 |  Abstract »  |  PDF »

Utility of Serum HER2 Extracellular Domain Assessment in Clinical Decision Making: Pooled Analysis of Four Trials of Trastuzumab in Metastatic Breast Cancer.

S. Lennon, C. Barton, L. Banken, L. Gianni, M. Marty, J. Baselga, and B. Leyland-Jones (2009)
J. Clin. Oncol. 27, 1685-1693
 |  Abstract »  |  Full Text »  |  PDF »

Value and Limitations of Measuring HER-2 Extracellular Domain in the Serum of Breast Cancer Patients.

A. F. Leary, W. M. Hanna, M. J. van de Vijver, F. Penault-Llorca, J. Ruschoff, R. Y. Osamura, M. Bilous, and M. Dowsett (2009)
J. Clin. Oncol. 27, 1694-1705
 |  Abstract »  |  Full Text »  |  PDF »

The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine.

J. S. Ross, E. A. Slodkowska, W. F. Symmans, L. Pusztai, P. M. Ravdin, and G. N. Hortobagyi (2009)
Oncologist 14, 320-368
 |  Abstract »  |  Full Text »  |  PDF »

Memo is a cofilin-interacting protein that influences PLC{gamma}1 and cofilin activities, and is essential for maintaining directionality during ErbB2-induced tumor-cell migration.

M. Meira, R. Masson, I. Stagljar, S. Lienhard, F. Maurer, A. Boulay, and N. E. Hynes (2009)
J. Cell Sci. 122, 787-797
 |  Abstract »  |  Full Text »  |  PDF »

HER-2 as a Target for Breast Cancer Therapy.

M. Ignatiadis, C. Desmedt, C. Sotiriou, E. de Azambuja, and M. Piccart (2009)
Clin. Cancer Res. 15, 1848-1852
 |  Full Text »  |  PDF »

Effects of Food on the Relative Bioavailability of Lapatinib in Cancer Patients.

K. M. Koch, N. J. Reddy, R. B. Cohen, N. L. Lewis, B. Whitehead, K. Mackay, A. Stead, A. P. Beelen, and L. D. Lewis (2009)
J. Clin. Oncol. 27, 1191-1196
 |  Abstract »  |  Full Text »  |  PDF »

Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations.

G. Sauter, J. Lee, J. M.S. Bartlett, D. J. Slamon, and M. F. Press (2009)
J. Clin. Oncol. 27, 1323-1333
 |  Abstract »  |  Full Text »  |  PDF »

Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis.

T. Ben-Kasus, B. Schechter, S. Lavi, Y. Yarden, and M. Sela (2009)
PNAS 106, 3294-3299
 |  Abstract »  |  Full Text »  |  PDF »

Incomplete surgical resection of ductal carcinomas in situ results in activation of ERBB2 in residual breast cancer cells.

C. F Singer, G. Hudelist, E.-M. Fuchs, W. Kostler, A. Fink-Retter, D. Gschwantler-Kaulich, M. Gnant, W. Lamm, M. Rudas, K. Czerwenka, et al. (2009)
Endocr. Relat. Cancer 16, 73-83
 |  Abstract »  |  Full Text »  |  PDF »

Association between frequent CpG island methylation and HER2 amplification in human breast cancers.

K. Terada, E. Okochi-Takada, S. Akashi-Tanaka, K. Miyamoto, K. Taniyama, H. Tsuda, K. Asada, M. Kaminishi, and T. Ushijima (2009)
Carcinogenesis 30, 466-471
 |  Abstract »  |  Full Text »  |  PDF »

Treatment of Mammary Carcinomas in HER-2 Transgenic Mice through Combination of Genetic Vaccine and an Agonist of Toll-Like Receptor 9.

L. Aurisicchio, D. Peruzzi, A. Conforti, S. Dharmapuri, A. Biondo, S. Giampaoli, A. Fridman, A. Bagchi, C. T. Winkelmann, R. Gibson, et al. (2009)
Clin. Cancer Res. 15, 1575-1584
 |  Abstract »  |  Full Text »  |  PDF »

Trastuzumab Reverses Letrozole Resistance and Amplifies the Sensitivity of Breast Cancer Cells to Estrogen.

G. Sabnis, A. Schayowitz, O. Goloubeva, L. Macedo, and A. Brodie (2009)
Cancer Res. 69, 1416-1428
 |  Abstract »  |  Full Text »  |  PDF »

A Novel Human Her-2/neu Chimeric Molecule Expressed by Listeria monocytogenes Can Elicit Potent HLA-A2 Restricted CD8-positive T cell Responses and Impact the Growth and Spread of Her-2/neu-positive Breast Tumors.

M. M. Seavey, Z.-K. Pan, P. C. Maciag, A. Wallecha, S. Rivera, Y. Paterson, and V. Shahabi (2009)
Clin. Cancer Res. 15, 924-932
 |  Abstract »  |  Full Text »  |  PDF »

The Clinical Utility of Tumor Markers.

B. Handy (2009)
Lab Med 40, 99-103
 |  Abstract »  |  Full Text »  |  PDF »

Cost-Effectiveness of Trastuzumab as Adjuvant Therapy for Early Breast Cancer: A Systematic Review.

A. L. Chan, H. W. Leung, C.-L. Lu, and S. J. Lin (2009)
Ann. Pharmacother. 43, 296-303
 |  Abstract »  |  Full Text »  |  PDF »

Blockade of the erbB2 Receptor Induces Cardiomyocyte Death through Mitochondrial and Reactive Oxygen Species-dependent Pathways.

L. I. Gordon, M. A. Burke, A. T. K. Singh, S. Prachand, E. D. Lieberman, L. Sun, T. J. Naik, S. V. N. Prasad, and H. Ardehali (2009)
J. Biol. Chem. 284, 2080-2087
 |  Abstract »  |  Full Text »  |  PDF »

Effect of Lapatinib on the Development of Estrogen Receptor-Negative Mammary Tumors in Mice.

T. E. Strecker, Q. Shen, Y. Zhang, J. L. Hill, Y. Li, C. Wang, H.-T. Kim, T. M. Gilmer, K. R. Sexton, S. G. Hilsenbeck, et al. (2009)
J Natl Cancer Inst 101, 107-113
 |  Abstract »  |  Full Text »  |  PDF »

Sex Hormone Levels, Breast Cancer Risk, and Cancer Receptor Status in Postmenopausal Women: the ORDET Cohort.

S. Sieri, V. Krogh, G. Bolelli, C. A. Abagnato, S. Grioni, V. Pala, A. Evangelista, C. Allemani, A. Micheli, G. Tagliabue, et al. (2009)
Cancer Epidemiol. Biomarkers Prev. 18, 169-176
 |  Abstract »  |  Full Text »  |  PDF »

Genetic Regulation of the Response to Her-2 DNA Vaccination in Human Her-2 Transgenic Mice.

O. Radkevich-Brown, J. Jacob, M. Kershaw, and W.-Z. Wei (2009)
Cancer Res. 69, 212-218
 |  Abstract »  |  Full Text »  |  PDF »

Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer.

I. H. Park, J. Ro, K. S. Lee, B. H. Nam, Y. Kwon, and K. H. Shin (2009)
Ann. Onc. 20, 56-62
 |  Abstract »  |  Full Text »  |  PDF »

HER-2 Targeting Agents and Antiangiogenic Therapy: Evolution of Adjuvant Therapy in Breast Cancer.

S. Sinclair, A. S. Zimmer, and S. M. Swain (2009)
ASCO Educational Book 2009, 3-10
 |  Abstract »  |  Full Text »  |  PDF »

Broad Antitumor Activity in Breast Cancer Xenografts by Motesanib, a Highly Selective, Oral Inhibitor of Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors.

A. Coxon, T. Bush, D. Saffran, S. Kaufman, B. Belmontes, K. Rex, P. Hughes, S. Caenepeel, J. B. Rottman, A. Tasker, et al. (2009)
Clin. Cancer Res. 15, 110-118
 |  Abstract »  |  Full Text »  |  PDF »

Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study.

J. Cortes, S. Di Cosimo, M. A. Climent, H. Cortes-Funes, A. Lluch, P. Gascon, J. I. Mayordomo, M. Gil, M. Benavides, L. Cirera, et al. (2009)
Clin. Cancer Res. 15, 307-314
 |  Abstract »  |  Full Text »  |  PDF »

Minimizing Cardiotoxicity While Optimizing Treatment Efficacy with Trastuzumab: Review and Expert Recommendations.

M. Martin, F. J. Esteva, E. Alba, B. Khandheria, L. Perez-Isla, J. A. Garcia-Saenz, A. Marquez, P. Sengupta, and J. Zamorano (2009)
Oncologist 14, 1-11
 |  Abstract »  |  Full Text »  |  PDF »

Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer.

M. Dowsett and A. K. Dunbier (2008)
Clin. Cancer Res. 14, 8019-8026
 |  Abstract »  |  Full Text »  |  PDF »

Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers.

S. Chia, B. Norris, C. Speers, M. Cheang, B. Gilks, A. M. Gown, D. Huntsman, I. A. Olivotto, T. O. Nielsen, and K. Gelmon (2008)
J. Clin. Oncol. 26, 5697-5704
 |  Abstract »  |  Full Text »  |  PDF »

Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235.

P. J.A. Eichhorn, M. Gili, M. Scaltriti, V. Serra, M. Guzman, W. Nijkamp, R. L. Beijersbergen, V. Valero, J. Seoane, R. Bernards, et al. (2008)
Cancer Res. 68, 9221-9230
 |  Abstract »  |  Full Text »  |  PDF »

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate.

G. D. Lewis Phillips, G. Li, D. L. Dugger, L. M. Crocker, K. L. Parsons, E. Mai, W. A. Blattler, J. M. Lambert, R. V.J. Chari, R. J. Lutz, et al. (2008)
Cancer Res. 68, 9280-9290
 |  Abstract »  |  Full Text »  |  PDF »

HER-2 Protein Overexpression in Metastatic Breast Carcinoma Found at Autopsy.

S. Kyoda, S. Kinoshita, H. Takeyama, K. Uchida, and T. Morikawa (2008)
Jpn. J. Clin. Oncol. 38, 743-747
 |  Abstract »  |  Full Text »  |  PDF »

Pharmacogenetics in Psychiatry: Are We Ready for Widespread Clinical Use?.

M. J. Arranz and S. Kapur (2008)
Schizophr Bull 34, 1130-1144
 |  Abstract »  |  Full Text »  |  PDF »

Delineation of HER2 Gene Status in Breast Carcinoma by Silver in Situ Hybridization is Reproducible among Laboratories and Pathologists.

A. Carbone, G. Botti, A. Gloghini, G. Simone, M. Truini, M. P. Curcio, P. Gasparini, A. Mangia, T. Perin, S. Salvi, et al. (2008)
J. Mol. Diagn. 10, 527-536
 |  Abstract »  |  Full Text »  |  PDF »

Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells.

A. Esparis-Ogando, A. Ocana, R. Rodriguez-Barrueco, L. Ferreira, J. Borges, and A. Pandiella (2008)
Ann. Onc. 19, 1860-1869
 |  Abstract »  |  Full Text »  |  PDF »

Acquired Resistance to Small Molecule ErbB2 Tyrosine Kinase Inhibitors.

F. L. Chen, W. Xia, and N. L. Spector (2008)
Clin. Cancer Res. 14, 6730-6734
 |  Abstract »  |  Full Text »  |  PDF »

Liquid-Based Fluorescence In Situ Hybridization Assay for Detection of ERBB2 Gene Amplification in Patients with Breast Cancer.

C.-H. Yeh, W. A. Whitmire III, and M. Albitar (2008)
Clin. Chem. 54, 1831-1839
 |  Abstract »  |  Full Text »  |  PDF »

Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers.

R. J. Leary, J. C. Lin, J. Cummins, S. Boca, L. D. Wood, D. W. Parsons, S. Jones, T. Sjoblom, B.-H. Park, R. Parsons, et al. (2008)
PNAS 105, 16224-16229
 |  Abstract »  |  Full Text »  |  PDF »

Polysomy 17 in Breast Cancer: Clinicopathologic Significance and Impact on HER-2 Testing.

I. Vanden Bempt, P. Van Loo, M. Drijkoningen, P. Neven, A. Smeets, M.-R. Christiaens, R. Paridaens, and C. De Wolf-Peeters (2008)
J. Clin. Oncol. 26, 4869-4874
 |  Abstract »  |  Full Text »  |  PDF »

Polysomy 17 and HER-2 Amplification: True, True, and Unrelated.

C. L. Rosenberg (2008)
J. Clin. Oncol. 26, 4856-4858
 |  Full Text »  |  PDF »

Suppression of the Negative Regulator LRIG1 Contributes to ErbB2 Overexpression in Breast Cancer.

J. K. Miller, D. L. Shattuck, E. Q. Ingalla, L. Yen, A. D. Borowsky, L. J.T. Young, R. D. Cardiff, K. L. Carraway III, and C. Sweeney (2008)
Cancer Res. 68, 8286-8294
 |  Abstract »  |  Full Text »  |  PDF »

Construction of a Fully Retargeted Herpes Simplex Virus 1 Recombinant Capable of Entering Cells Solely via Human Epidermal Growth Factor Receptor 2.

L. Menotti, A. Cerretani, H. Hengel, and G. Campadelli-Fiume (2008)
J. Virol. 82, 10153-10161
 |  Abstract »  |  Full Text »  |  PDF »

To Advertise   |   Find Products